These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 28110331

  • 1. Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution.
    Koyama N, Watanabe Y, Iwai Y, Kawamura R, Miwa C, Nagai Y, Hagiwara K, Koyama S.
    Chemotherapy; 2017; 62(3):151-158. PubMed ID: 28110331
    [Abstract] [Full Text] [Related]

  • 2. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R, Spanish Lung Cancer Group.
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL, Han G, Peng M, Weng YM, Yuan JP, Yang GF, Yu JM, Song QB.
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [Abstract] [Full Text] [Related]

  • 9. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
    Zhou Q, Yang JJ, Chen ZH, Zhang XC, Yan HH, Xu CR, Su J, Chen HJ, Tu HY, Zhong WZ, Yang XN, Wu YL.
    J Hematol Oncol; 2016 Sep 13; 9(1):86. PubMed ID: 27619632
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
    Watanabe S, Inoue A, Nukiwa T, Kobayashi K.
    Anticancer Res; 2015 Dec 13; 35(12):6957-61. PubMed ID: 26637922
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
    Yang W, Gao Y, Li X, Zhang J, Liu T, Feng X, Pan H, Yang X, Xie S, Feng X, Lv Z, Wang Y, Chen Z, He J.
    World J Surg Oncol; 2017 Nov 06; 15(1):197. PubMed ID: 29110716
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S.
    Anticancer Res; 2015 Jul 06; 35(7):3885-91. PubMed ID: 26124334
    [Abstract] [Full Text] [Related]

  • 17. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
    Reguart N, Remon J.
    Future Oncol; 2015 Jul 06; 11(8):1245-57. PubMed ID: 25629371
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.